Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT05419492

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

Conditions: Dravet Syndrome

Sex: All

Ages: 6 Months – 17 Years

Healthy volunteers: No

Phase: PHASE1, PHASE2

Enrollment: 47

Sponsor: Encoded Therapeutics

Location: UCSF Benioff Children's Hospitals San Francisco California

Summary

ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to \

Eligibility Criteria

Inclusion Criteria: * Participant must be aged between ≥6 months and \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05419492). StuddyBuddy aggregates publicly available trial information.